Abstract: Ester derivatives of gamma-aminobutyric acid (GABA) and GABA analogues which cross the blood-brain barrier are disclosed, as well as methods of synthesizing and using the compounds.The ester derivatives have the formula: ##STR1## where A is a radical compound having at least one esterifiable OH group; n varies from one to the total number of esterifiable OH group contained in A; and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen or a substituent.

Abstract: A method of reducing the negative effects of heavy metals and a method of preventing or alleviating immunodeficiency, hypertension and dermatitis in mammals is disclosed. In these methods pharmaceutical compositions are administered to a mammal in need thereof. The particular pharmaceutical composition includes a reducing, preventing or alleviating effective amount, for the particular condition, of at least one isomer of inositol triphosphate.

Abstract: Compositions useful in the treatment of neurological degenerative disorders which are characterized by reduced levels of acetylchone from neurons, as well as methods of use therefor are described. The compositions include pyritinol or a pyritinol derivative, analogue or metabolite, and choline or a source of choline.

Abstract: The invention pertains to a method and pharmaceutical compositions for treating, preventing or reducing neurodegeneration associated with chronic central nervous system or hypoxic, ischemic and hypoglycemic injury to the central nervous system and for the treatment of anxiety through the use of 2-amino-.omega.-phosphonoalkanoic acids having a cycloalkyl group bridging adjacent carbons on the alkyl chain, their pharmaceutically acceptable salts and derivatives as neuroprotectants and anxiolytics.

Abstract: Disclosed are novel opthalmic solutions useful for the treatment of ocular hypertension and glaucoma. These contain mabuterol as a preferred active ingredient.

Abstract: The present invention provides a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1, are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2, are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3, are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion.The invention also provides a method of treating a subject having a condition associated with the presence of free radicals in quantities sufficient to cause undesirable symptoms.

Abstract: The invention relates to weight gain-increasing compositions, particularly fodder supplement, premix, drinking water supplement, bolus and/or microcapsule containing 0.001 to 90% by weight of 1-(3,5-dihydroxyphenyl)-2-(tertiary butylamino)-ethanol or a physiologically acceptable acid addition salt thereof as active ingredient in admixture with inert solid and/or liquid carrier(s).

Abstract: Calcium modulators can be effectively used to treat cardiovascular and cerebral toxicity induced by materials that alter the normal interaction of neurotransmitters with the calcium transport mechanisms of myocardial and cerebral cells. For example, calcium modulators can be used as an antidote to the lethal and chronic toxicity of cocaine and related indirectly acting sympathomimetic amines, imipramine and other tricyclic antidepressants, ganglionic stimulating drugs, and other toxic substances such as organophosphorus compounds that cause accumulations of neurotransmitters. Calcium modulators can also be used as an antidote to substances whose toxicity is based upon anticholinesterase activity. In addition, calcium modulators can be used as antagonists to the various types of toxic substances.

Abstract: A method is described for treating and/or preventing pulmonary oedema in patients comprising administering a suphonylurea compound or a pharmaceutically acceptable salt thereof to patients who suffer from or are susceptible to oedema. Glucose may also be simultaneously administered to the patients to prevent hypoglycemia.

Abstract: A method of treatment of depressive states which comprises administering in mammals in need thereof an effective amount of a compound ##STR1## R.sub.1 represents hydrogen, a halogen atom, a cyano group a nitro group, an acetyl group or a trifluoromethyl group;R.sub.2 represents a hydroxyl group, in which case R.sub.3 represents a hydrogen atom, or R.sub.2 and R.sub.3 taken together represent an additional bond between the carbon atoms by which they are carried; andR.sub.4 represents a 2-oxopyrrolidin-1-yl or 2-oxopiperid-1-yl group or a heterocyclic group selected from 1H-pyrid-2-on-1-yl, 1H-pyridazin-6-on-1-yl, 1H-pyrimidin-2-on-1-yl, 1H-pyrimidin-6-on-1-yl, 1H-pyrazin-2-on-1-yl and 1H-thiopyrid-2-on-1-yl groups which are unsubstituted or monosubstituted or disubstituted by a C.sub.1 -C.sub.4 alkyl group, a halogen atom or a hydroxyl, nitro, amino or carboxyl group and the pharmaceutically acceptable salts thereof.

Abstract: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at least one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated--bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e, R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R'.sub.a and R".sub.

Abstract: There are disclosed combination products useful for the treatment and/or prevention of a first or recurrent myocardial infarction or a first or recurrent stroke. Said combination products comprise low doses of an oral anticoagulant, preferably warfarin and platelet inhibiting agents, including non-steroidal antiinflammatory agents and preferrably aspirin.

Abstract: A method for treating viral infections in a patient with a benzodiazepine derivative compound and compositions.

Abstract: Method for inhibiting the development of tolerance in the analgesic treatment with morphine of a subject in need of said treatment, comprising administering systemically and contemporarily an effective analgesic dose of morphine and an amount of dapiprazole of from 1/4 to 1 part by weight to 1 part by weight of said analgesic dose of morphine.Pharmaceutical composition useful in the said method.

Abstract: The invention relates to a method of treating a catabolic dysfunction in an animal, which comprises administering to an animal a therapeutically effective amount of glutamine, or an analog thereof.

Abstract: This invention relates to an aminoglycoside composition having reduced nephrotoxicity induced by the aminoglycoside which comprises a selected aminoglycoside and a compound present in an effective amount selected from the group consisting of (a) at least one 7-(oxoalkyl)1,3-dialkyl xanthine of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are independently selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, straight-chain or branched chain alkoxyalkyl and hydroxyalkyl radicals; and A is a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group; (b) a compound of the formula ##STR2## wherein at least one of R.sub.3 and R.sub.4 is a branched hydroxyalkyl group of the formula ##STR3## with a tertiary alcohol function, which R.sub.6 stands for an alkyl group with 1 to 3 carbon atoms and n stands for a whole number from 2 to 5, the other R.sub.3 or R.sub.

Abstract: A method is described for weight reduction of an individual dieter which comprises administering pantothenic acid or derivative thereof which will generate pantothenic acid in the body in conjunction with a program of reduced caloric consumption.

Abstract: This invention relates to a method of increasing cranial arterioles in warm-blooded animals comprising administering an effective amount of the compound having the formula 1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine-3-.beta.-methoxyethyl ester)-5-(isopropyl ester), to said animals to achieve vessel proliferation.

Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.

Abstract: A pharmaceutical composition and process for administering non-steroidal drugs which are protected againsts injury to the gastrointestinal tract by a combination of certain H.sub.1 - and H.sub.2 -receptor blockers.